Business Context and Reporting Period
Company: Accuray Incorporated
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 27, 2008 (Fiscal Q1 2009)
Business Overview: Accuray designs, develops, and sells the CyberKnife system, an image-guided robotic radiosurgery system for treating solid tumors. The company operates globally with subsidiaries in Europe, Asia, and the Americas. As of the period end, 145 systems were installed worldwide.
Key Financial Metrics
| Metric (in thousands) | Q1 2009 | Q1 2008 |
|---|---|---|
| Total Net Revenue | $55,857 | $48,646 |
| Gross Profit | $28,429 | $25,911 |
| Gross Margin | 50.9% | 53.3% |
| Operating Loss | $(4,238) | $139 |
| Net Loss | $(3,179) | $2,265 |
| Cash and Cash Equivalents | $27,196 | $192,111 |
| Short-term Marketable Securities | $91,471 | N/A |
| Long-term Marketable Securities | $37,988 | N/A |
| Total Backlog | $644.4 million | N/A |
Note: Cash flow from operating activities was a net use of $521,000 for the quarter, compared to a net use of $11.4 million in the prior year period.
Material Changes vs. Prior Period
- Revenue Growth: Total net revenue increased 14.8% to $55.9 million, driven primarily by a $8.9 million increase in service revenue due to a higher number of customer sites under service plans.
- Profitability Decline: The company reported a net loss of $3.2 million, a reversal from a net income of $2.3 million in the prior year. This was driven by increased operating expenses and a $1.3 million inventory write-down.
- Expense Increases:
- Cost of Revenue: Increased $4.7 million (to $27.4 million), largely due to higher service costs and a $1.2 million increase in inventory reserves for obsolete parts.
- Selling & Marketing: Increased $3.3 million (to $13.5 million) due to trade show timing and headcount increases.
- General & Administrative: Increased $2.5 million (to $10.4 million), primarily due to $1.7 million in non-recurring employee separation costs.
- Shared Ownership Revenue: Decreased $1.3 million as units were sold out of the program.
Guidance, Risks, and Unusual Items
Material Weaknesses in Internal Controls
The company identified a new material weakness in internal controls over financial reporting regarding inventory processes. An investigation into allegations of improprieties resulted in a $1.3 million adjustment to inventory and cost of revenue for obsolete items. Additionally, a previously reported material weakness regarding revenue recognition is still being remediated.
Liquidity and Investments
The company holds approximately $20.4 million in auction-rate securities (ARS) which have become illiquid due to failed auctions. While these are backed by federal student loans, the company may not have access to these funds until auctions succeed or securities are called. Management believes current cash resources are sufficient for at least 12 months.
Regulatory and Reimbursement Risks
CMS announced a decrease in 2009 Medicare reimbursement rates for CyberKnife procedures. Additionally, new Stark Law regulations effective October 2009 may restrict physician-owned entities from acquiring the system, potentially impacting future sales.
Backlog
Total backlog was $644.4 million, consisting of $451.5 million in non-contingent backlog and $192.9 million in contingent backlog.
Investor Verification Checklist
- Inventory Valuation: Verify the adequacy of inventory reserves following the $1.3 million write-down and the new material weakness in inventory controls.
- Liquidity of ARS: Assess the risk associated with the $20.4 million in illiquid auction-rate securities and the company's ability to access these funds if needed.
- Reimbursement Impact: Monitor the effect of the 2009 CMS reimbursement rate reductions on customer demand and sales cycles.
- Internal Control Remediation: Track the progress of remediation efforts for both the revenue recognition and inventory control material weaknesses.
- Backlog Conversion: Evaluate the probability of converting the $192.9 million contingent backlog into revenue, given regulatory and financing hurdles.